Demarcating the benefits of hybrid closed loop therapy in pregnant women with type 1 diabetes
The role of hybrid closed-loop systems in the clinical management of type 1 diabetes is rapidly expanding. Randomised controlled trials have shown life-changing clinical and quality-of-life benefits beyond those that can be obtained by use of continuous glucose monitoring (CGM) with an insulin pump or multiple daily injection therapy.1 Meta-analyses of trial data confirm substantial glycaemic improvements in people of all ages, with 8–12 percentage points higher time spent in the target glucose range of 3·9–10·0 mmol/L, and lower mean glucose with less or no additional hypoglycaemia.
